FKBP immunophilin patents for neurological disorders

Bibliography

• STEINER JP, DAWSON TM, FOTUHI M et al.: High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature (1992) 358:584–587.
   PubMed Web of Science ®Google Scholar
• LYONS WE, STEINER JP SNYDER SH, DAWSON TM: Neuronal regeneration enhances the expression of the immunophilin FKBP-12.j Neurosci. (1995) 15:2985–2994.
   PubMed Web of Science ®Google Scholar
• SNYDER SH, SABATINI DM: Immunophilins and the nervous system. Nat. Med. (1995) 1:32–37.
   PubMed Web of Science ®Google Scholar
• GOLD BG: FK506 and the role of the immunophilin FKBP-52 in nerve regeneration. Drug Metab. Rev. (1999) 31:649–663.
   PubMed Web of Science ®Google Scholar
• GOLD BG: Neuroimmunophilin ligandsand the role of steroid hormone chaperone proteins in nerve regeneration. In: Immunophilins in the Brain. FKBP-ligands: Novel strategies for the treatment of neurodegenerative disorders. Gold BG, Fischer G, Herdegen T (Eds), Barcelona (2000):3–22.
   Google Scholar
• GOLD BG: Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin. Investig. Drugs (2000) 9:2331–2342.
   PubMed Web of Science ®Google Scholar
• GOLD BG, VILLAFRANCA JE: Neuroimmunophilin ligands: the development of novel neuroregenerative/ neuroprotective compounds. Curr. Top. Med. Chem. (2003) 3:1368–1375.
   PubMed Web of Science ®Google Scholar
• • A good review on progress and future development of nonimmunosuppressant derivatives for the treatment of neurological disorders.
   Google Scholar
• SCHREIBER SL, CRABTREE GR: The mechanism of action of cyclosporin A and FK506. ImmunoL Today. (1992) 13:136–142.
   PubMedGoogle Scholar
• ALNEMRI ES, FERNANDES-ALNEMRI T, NELKI DS et al.: Overexpression, characterization, and purification of a recombinant mouse immunophilin FKBP-52 and identification of an associated phosphoprotein. Proc. NatL Acad. Sci. USA (1993) 90:6839–6843.
   PubMed Web of Science ®Google Scholar
• SIGAL NH, DUMONT FJ: Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann. Rev. Immunol. (1992) 10:519–560.
   PubMed Web of Science ®Google Scholar
• STARZL TE, MAKOWKA L, TODO S: FK-506: A potential breakthrough in immunosuppression. Transplant. Proc. (1987) 19:S3–S104.
   Google Scholar
• STARZL TE, TODO S, FUNG J et al.: FK-506 for liver, kidney, and pancreas transplantation. Lancet (1989) 2:1000–1004.
   PubMed Web of Science ®Google Scholar
• HOFFMAN AL, MAKOWKA L, BANNER B et al.: The use of FK-506 for small intestine allotransplantation: inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 49:483–490.
   PubMed Web of Science ®Google Scholar
• DUBERNARD J-M, OWEN E, HERZBERG G et aL: Human hand allograft: report on first 6 months. Lancet (1999) 353:1315–1320.
   PubMedGoogle Scholar
• JONES JW, GRUBER SA, BARKER JH,BREIDENBACH WC: Successful hand transplantation: one year follow-up. N Engl. J. Med. (2000) 343:468–473.
   PubMed Web of Science ®Google Scholar
• • First report on a successful hand transplation using FK-506 as immunosuppressant and indicating that the drug improves nerve regeneration in humans.
   Google Scholar
• MACKINNON SE, DOOLABH VB, NOVAK CB, TRULOCK EP: Clinical outcome following nerve allograft transplantation. Plast. Reconstr. Surg (2001) 107:1419–1429.
   PubMed Web of Science ®Google Scholar
• GOLD BG, STORM-DICKERSON T, AUSTIN DR: The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury. Restor. NeuroL Neurosci. (1994) 6:287–296.
   PubMed Web of Science ®Google Scholar
• • First report on the discovery of the nerve regenerative activity of FK-506 in vivo.
   Google Scholar
• GOLD BG, KATOH K, STORM-DICKERSON T: The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. 1 Neurosci. (1995) 15:7509–7516.
   Google Scholar
• WANG MS, ZELENY-POOLEY M, GOLD BG: Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in rat sciatic nerve. J. PharmacoL Exp. Ther. (1997) 282:1084–1093.
   PubMed Web of Science ®Google Scholar
• PEI G, GU L, YU L: A preliminary reportof two cases of human hand allograft. Zhonghua Yi Xue Za Zhi. (2000) 80:417–421.
   PubMedGoogle Scholar
• MARGREITER R, BRANDACHER G, NINKOVIC M et al.: A double-hand transplant can be worth the effort! Transplantation (2002) 74:85–90.
   Google Scholar
• GOLD BG: FK506 and the role of immunophilins in nerve regeneration. MoL NeurobioL (1997) 15:285–306.
   PubMed Web of Science ®Google Scholar
• SNYDER SH, LAI MM, BURNETT PE: Immunophilins in the nervous system. Neuron (1998) 21:283–294.
   PubMed Web of Science ®Google Scholar
• STEINER JP, HAMILTON GS, ROSS DT et al.: Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc. Natl. Acad. Sci. USA (1997) 94:2019–2024.
   PubMed Web of Science ®Google Scholar
• •• First report on two Guilfordnonimmunosuppressant derivatives of FK-506 that are effective in two toxic-chemical models of Parkinson's disease.
   Google Scholar
• STEINER JP, CONNOLLY MA, VALENTINE HL et aL: Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat. Med. (1997) 3:421–428.
   PubMed Web of Science ®Google Scholar
• •• First report on two Guilfordnonimmunosuppressant derivatives of FK-506 that retain its nerve regenerative activity, revealing the separation of these two properties.
   Google Scholar
• GOLD BG, ZELENY-POOLEY M, WANG M-S, CHATURVEDI P, ARMISTEAD DM: A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. Exp. NeuroL (1997) 147:269–278.
   PubMed Web of Science ®Google Scholar
• •• First report of a Vertex nonimmunosuppressant derivative of FK-506 having nerve regenerative activity and demonstrating separation of immunosuppressive and nerve regeneration properties.
   Google Scholar
• GOLD BG, ZELENY-POOLEY M, CHATURVEDI P, WANG M-S: Oral administration of a nonimmunosuppressant FKBP-12 ligand speeds nerve regeneration. Neuroreport (1998) 9:553–558.
   PubMed Web of Science ®Google Scholar
• • First report of an orally activity immunophilin compound speeding nerve regeneration.
   Google Scholar
• COSTANTINI LC, COLE D, CHATURVEDI P, ISACSON 0: Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease. Eur. Neurosci. (2001) 13:1085–1092.
   PubMedGoogle Scholar
• GOLD BG, ARMISTEAD DM, WANG M-S: Non-FKBP-12 neuroimmunophilin ligands increase neurite outgrowth and accelerate nerve regeneration. J. Neurosci. Res. (2005) 80:56–65.
   PubMed Web of Science ®Google Scholar
• •• Reports the discovery that Vertexnonimmunosuppressant derivatives of FK-506 that do not bind to FKBP-12 are neurotrophic and that one such compound is orally activity in speeding nerve regeneration.
   Google Scholar
• GOLD BG, DENSMORE V SHOU W, MATZUK MM, GORDON HS: Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J. PharmacoL Exp. Ther. (1999) 289:1202–1210.
   PubMed Web of Science ®Google Scholar
• • Demonstrates that the neurotrophic activity is independent of FKBP-12 and implicates involvement of FKBP-52, a component of steroid receptor complexes.
   Google Scholar
• PERDEW GH, WHITELAW ML: Evidence that the 90-kDa heat shock protein (HSP90) exists in cytosol in heteromeric complexes containing HSP70 and three other proteins with M, of 63,000, 56,000, and 50,000.1 Biol. Chem. (1991) 266:6708–6713.
   PubMed Web of Science ®Google Scholar
• SANCHEZ ER: Hsp56: A novel heat shock protein associated with untransformed steroid receptor complexes. J. Biol. Chem. (1990) 265:22067–22070.
   PubMed Web of Science ®Google Scholar
• TAI P-KK, ALBERS MW, CHANG H, FABER LE, SCHREIBER SL: Association of a 59 kDa immunophilin with the glucocorticoid receptor complex. Science (1992) 256:1315–1318.
   PubMed Web of Science ®Google Scholar
• GOLD BG, ZHONG YP: FK506 requiresstimulation of the extracellular signal regulated kinase 1/2 and the steroid receptor chaperone protein p23 for neurite elongation. Neurosignals (2004) 13:122–129.
   PubMedGoogle Scholar
• GOLD BG, VODA J, YU X, MCKEON G, BOURDETTE DN: FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis. J. Neurosci. Res. (2004) 77:367–377.
   PubMed Web of Science ®Google Scholar
• PRICE RD, YAMAJI T, YAMAMOTO H et al.: FK1706, a novel non-immunosuppressive immunophilin ligand: neurotrophic activity and mechanism of action. Eur. j PharmacoL (2005) 509:11–19.
   PubMed Web of Science ®Google Scholar
• HAMILTON GS, HUANG W, CONNOLLY MA et al.: FKBP12-binding domain analogues of FK506 are potent, nonimmunosuppressive neurotrophic agents in vitro and promote recovery in a mouse model of Parkinson's disease. Bioorg. Med. Chem. (1997) 7:1785–1790.
   Google Scholar
• HAMILTON GS, STEINER JP: Neuroimmunophilin ligands as novel therapeutics for the treatment of degenerative disorders of the nervous system. Curr. Pharm. Des. (1997) 3:405–428.
   Web of Science ®Google Scholar
• HAMILTON GS, STEINER JP: Neuroimmunophilin ligands as novel therapeutics for the treatment of degenerative disorders of the nervous system. Curr. Pharm. Des. (1997) 3:405–428.
   Web of Science ®Google Scholar
• CHOI C, LI JH, VAAL M et al.: Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1421–1428.
   PubMedGoogle Scholar
• HAMILTON GS, WU YQ, LIMBURG DC et al.: Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects. 1 Med. Chem. (2002) 45:3549–3557.
   Google Scholar
• HOLT DA, LUENGO JI, YAMASHITA DS et al.: Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP-12. J. Am. Chem. Soc. (1993) 115:9925–9938.
   Web of Science ®Google Scholar
• DRAGOVICH PS, BARKER JE, FRENCH Jet al.: Structure-based design of novel, urea-containing FKBP12 inhibitors. J. Med. Chem. (1996) 39:1872–1884.
   Google Scholar
• WU YQ, WILKINSON DE, LIMBURG D et al.: Synthesis of ketone analogues of prolyl and pipecolyl ester FKBP12 ligands. J. Med. Chem. (2002) 45:3558–3568.
   PubMedGoogle Scholar
• CAMERON AM, STEINER: JP, SABATINI DM et al. : Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. Proc. Nail. Acad. Sci. USA (1995) 92:1784–1788.
   PubMedGoogle Scholar
• DUBOWCHIK GM, VRUDHULA VM, DASGUPTA B et al.: 2-Aryl-2,2-difluoroacetamide FKBP12 ligands: synthesis and X-ray structural studies. Org. Lett. (2001) 3:3987–3990.
   PubMedGoogle Scholar
• GOLD BG, NUTT JG: Neuroimmunophilin ligands in the treatment of Parkinson's disease. Curr. Opin. Pharmacol. (2002) 2:82–86.
   PubMed Web of Science ®Google Scholar
• MULLIN S, MANI N, GROSSMAN TH: Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). Antimicrob. Agents Chemother. (2004) 48:4171–4176.
   PubMed Web of Science ®Google Scholar
• • Reports the structure of timcodar.
   Google Scholar